With established sites in India and a strong focus on the USA and Europe, we are expanding into new geographies to establish ourselves as a leading CDMO provider.
Following the upcoming development of a new R&D and pharmaceutical manufacturing facility near Princeton, New Jersey, in the USA, we aim to create access equity for early-stage biological assets by offering cost-effective local manufacturing capabilities to companies working with novel molecules.
Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, today announced that its two facilities in Pune have received European Union (EU) GMP certification to provide commercial-scale microbial and mammalian drug substance supply and drug product fill/finish and packaging.
A platform that pushes your project further
Unlocking higher yields across a range of biologics at significantly lower costs to you, our patented continuous bioprocess manufacturing platform EnzeneX™ represents the pinnacle of our ongoing commitment to innovation.
Our suite of CDMO solutions is designed to provide everything you need, from cell line development to fill and finish. With a fully-integrated approach to your product, we provide you with a single, direct and streamlined route to market.
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.